Sentences with phrase «level impact of the program»

Not exact matches

But the big financial push by Stanford raises startup culture to a new level, far exceeding the impact of accelerator programs and business plan competitions offered by most universities.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

While the elements of the Total Rewards Program are intended to motivate and encourage employees at all levels of HP to drive performance, there is a different emphasis on certain elements of the Total Rewards Program based on an employee's position and ability to impact HP's financial results.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

As a continuation of its ethical sourcing commitment, Starbucks will launch a pilot program with select coffee farmers in Costa Rica, Colombia and Rwanda to develop next - level data technology to log and share real - time information along the journey of coffee beans with the aim of driving positive impact to smallholder farmers within its supply chain.

We have also questioned the impact of the restraint measures on direct program expenses — total expenses less public debt charges and major transfers to individuals and other levels of government.

Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.

Although billions of dollars are being expended annually on family planning services in less - developed countries, and such programs have been promoted by various governments at the national level for four decades, there are only a few studies that have attempted to measure the demographic and health impact of family planning against a «control group» — a similar area which lacks the service.

Directly or indirectly, this philosophy of ministry - church should be a big box with programs for people at every level of spiritual maturity to consume and engage - has impacted every evangelical church in the country.

The VITAL Program not only assists food producers in assessing the potential impact of allergen cross contact in each of their products but also specifies a particular precautionary allergen statement to be used according to the level of cross contact identified.

Programs vary little in cost per year of service regardless of the professional level of the provider.13 However, programs that have a lifetime impact have a higher benefit / cost ratio than do those with limited and short - livedPrograms vary little in cost per year of service regardless of the professional level of the provider.13 However, programs that have a lifetime impact have a higher benefit / cost ratio than do those with limited and short - livedprograms that have a lifetime impact have a higher benefit / cost ratio than do those with limited and short - lived impact.

For example, understanding how, and at what level, the average family participates in the program will provide context to any variation in impacts we find in the health of families.

Legislator Casey Jordan took up the measure and said the Senate's bill would require funding of any state program or expenditure item that impacts lower levels of government, to be paid for by the state.

Health Department, NYU to Collaborate On Study «NIH Grant Will Fund Window Replacement / Lead Reduction Impact Investigation» The Oneida County Health Department's Lead Primary Prevention Program has been asked to participate in a study funded through a grant from the National Institute of Health (NIH) that will determine the impact of window replacement on lead dust levels, Oneida County Executive Anthony J. Picente, Jr. announced Impact Investigation» The Oneida County Health Department's Lead Primary Prevention Program has been asked to participate in a study funded through a grant from the National Institute of Health (NIH) that will determine the impact of window replacement on lead dust levels, Oneida County Executive Anthony J. Picente, Jr. announced impact of window replacement on lead dust levels, Oneida County Executive Anthony J. Picente, Jr. announced today.

Alabdulkader said the new reports «will provide NSTIP with a precise added value to assess the level of achievement of this program, and its impact on the R&D movements at the national and international levels.»

In order to project the impact of proposed cutbacks to U.S. - funded programs in South Africa, which has the greatest prevalence of HIV infection of any country, and the west African nation of Côte d'Ivoire, which has a different kind of epidemic and a different level of foreign aid dependency, the researchers used a widely - published mathematical model along with epidemiologic and cost data from each country to project the outcomes of potential programmatic responses.

The interaction occurred 149 minutes into the three - hour program, drawing in several candidates who repudiated the idea of enacting an «insurance policy» to guard against the risk of sea - level rise and other impacts of planetary warming.

«The SAFE - T program is a total team effort with a high level of collaboration between Temple nurses and physicians, and it's inspiring to see the impact that this program is having on the well - being of our patients and their families,» says Jennifer Rodriguez, BSN, RN, Director of Nursing Services at TUH.

Finally, the authors analyzed the impact of high federal funding levels in concert with expansion of the Medicaid program across all states.

Several studies echo a high level of satisfaction among short course participants and found measurable impacts, but it is important for students to come in with realistic expectations and make an effort to further their learning after the program is done.

This program, for candidates who have completed their postdoctoral training but with less than 4 years of subsequent experience, covers topics in general neuroscience and «seeks applicants working on problems that, if solved at the basic level, would have immediate and significant impact on clinically relevant issues.»

Many of the concerns relate to safety, in part because the impact of tinkering with cells at that level may not be completely evident for years or even generations, said Debra Mathews, assistant director for science programs at the Berman Institute of Bioethics at Johns Hopkins University.

However, the level of parasite mixing within and between geographical locations is likely to impact the effectiveness and durability of control interventions and thus should be taken into consideration when developing control programs.

True Health's health management program can help patients understand their lab results, and the impact of abnormal hormone levels on the body's physiologic processes.

The impact of the program is evaluated both at teachers» level, as well as at students» level.

Critics will continue to point to the fact that no impacts of the program have been observed in math, or that applicants from SINI schools, who were a service priority, have not demonstrated statistically significant achievement gains at the subgroup level, as reasons to characterize these findings as disappointing.

The authors of the study, Anna J. Egalite and Jonathan N. Mills, used the state's student - level database as well as U.S. Census data to examine the voucher program's impact on integration in the 2012 - 13 school year.

Specifically, he will work with the PI and core project staff to develop an analysis plan, direct the evaluation of the efficacy of the Core Knowledge Language Arts Listening and Learning Read Aloud Program, articulate the fully specified multi-level models used to estimate treatment impacts on child - level vocabulary, listening comprehension and domain knowledge outcomes, and guide the secondary analyses that examine whether the quality of read alouds mediate treatment effects on child outcomes and the baseline, child - level moderators of treatment effects.

All three levels of delivery include pre - and post-session surveys, the results of which, along with other feedback, will be used to evaluate the impact of the program and future needs.

And school and system leaders use data to evaluate the impact of school - wide and system - wide programs and initiatives to raise achievement levels and close equity gaps.

To make this level of impact possible, however, they needed to create a program that could quickly scale to multiple regions across the country.

Most research on the impact of early - childhood programs has focused on structural measures of quality, such as the teacher's educational level or staff ratios, or on the effects of classroom quality, broadly construed.

Our strictest test of the program's impact indicates that NLP schools show higher scores of 1.5 percentile points and a 2.5 higher percentage achieving at least level 4 in mathematics.

To make accurate decisions about the quality of teaching and the impact of school programs, Willett and Singer urge policymakers to examine not what different classes of children know at each grade level, but how the knowledge and skills of specific groups change over time.

To analyze the program's impact on public schools, we collected school - level test scores on the 2001 - 02 and 2002 - 03 administrations of the FCAT and the Stanford - 9, a national norm - referenced test that is given to all Florida public school students around the same time as the FCAT.

The Commission will examine factors that impact spending in education, including: school funding and distribution of State Aid; efficiency and utilization of education spending at the district level; the percentage of per - pupil funding that goes to the classroom as compared to administrative overhead and benefits; approaches to improving special education programs and outcomes while also reducing costs; identifying ways to reduce transportation costs; identifying strategies to create significant savings and long - term efficiencies; and analysis of district - by - district returns on educational investment and educational productivity to identify districts that have higher student outcomes per dollar spent, and those that do not.

We use the state's student - level database to examine the voucher program's impact on integration in the 2012 — 13 school year, the program's initial year of statewide operation.

The Executive Leadership Program for Educators at Harvard University in association with The Wallace Foundation will emphasize midcareer development of teams of high - level education leaders that share responsibility for making changes in their organizations and across their states to broadly improve school leadership and its impact on student achievement.

Any direct or indirect erosion of Impact Aid through a voucher program will reduce the Impact Aid funding currently going to these districts, and would also place a great financial burden on the local community, which would be left to fund public schools with an already low level of state and local tax revenue.

As one program leader noted, the «district / school needs to be realistic about the level of impact that can be expected», given the amount of release time that teacher leaders have to work with teachers.

The Interdisciplinary Master of Arts (MA) degree program in Educational Leadership and Special Education Administration prepares candidates to become effective leaders and managers of educational programs and services at both the school building and school district levels of impact.

degree program in Educational Leadership and Special Education Administration prepares candidates to become effective leaders and managers of educational program and services at both the school building and school district levels of impact.

LEAP is defining and articulating the teacher practices that best meet individual student needs; determining the school - and classroom - level models that best personalize learning; and constructing the research methods and tools to best evaluate the impact of personalized learning and edtech programs on student achievement.

The PDS program was recognized at the national level by the Council of Great City Schools with the 2015 Shirley Schwartz Urban Education Impact Award.

The district school board shall adopt a procedure for verifying the competency levels of all persons who participate in the career development program and a procedure to determine the outcomes and results of the program and impact on student performance.

While attainment levels are important for setting high expectations for students and schools, growth more accurately reflects the impact of a school, program or teacher.

The wide range of experiences and background help build a robust program that propels our members to the next level of their careers and impact.

This interview features insights from the article «Predictive Validity and Impact of CAEP Standard 3.2: Results From One Master's - Level Teacher Preparation Program,» written by Carla Evans of the University of New Hampshire.

While it is still too early to measure the full impact of RTT, what is clear is that the program inspired major policy changes at the state level.

There are no studies, for example, that measure the impact of the program using school - level, value - added data, which measures the contribution that schools make to student progress.